Arcturus Therapeutics Holdings Inc.
ARCTNASDAQHealthcareBiotechnology
As of Oct 23, 2026 close
- Market cap
- $279.68M
- P/E (TTM)
- -
- Forward P/E
- -
- Dividend yield
- -
- 52-week range
- $5.50$24.17
- Volume (live)
- -
- Avg. volume (3M)
- 739.83K
Arcturus Therapeutics Holdings (ARCT) Stock Price & Financial Analysis
Arcturus Therapeutics Holdings Stock Price Chart
Loading chart...
Financial Metrics & Key Statistics
Fundamental metrics, valuation ratios, and profitability indicators
| Day's Range | $9.75 - $10.69 |
|---|---|
| 52-Week High | $24.17 |
| 52-Week Low | $5.50 |
| Open | $10.59 |
| Volume (last close) | 474.42K |
| Average Volume (3M) | 739.83K |
| Revenue (TTM) | 20.80M |
|---|---|
| Net Income (TTM) | -93.28M |
| Free Cash Flow (TTM) | -73.05M |
| EPS (TTM) | −$3.35 |
| Profit Margin | -448.38% |
| Operating Margin | -495.81% |
| Return on Equity (ROE) | -54.29% |
| Debt to Equity | 0.13 |
| Annual Dividend | $0.00 |
|---|---|
| Dividend Yield | 0.00% |
| Market Cap | 279.68M |
|---|---|
| Shares Outstanding | 28.42M |
| Price to Sales (P/S) | 13.44 |
| Price to Book (P/B) | 1.63 |
| EV/EBITDA | -1.57 |
| 50-Day MA | $13.23 |
|---|---|
| 200-Day MA | $8.84 |
| 1-Year Change | −10.58% |
Source: Market prices and company fundamentals. Data as of Oct 23, 2026. Data sources and methodology
Arcturus Therapeutics Holdings at a Glance
As of the Oct 23, 2026 close, Arcturus Therapeutics Holdings (ARCT) has a market capitalization of $279.68M. The stock trades at 13.4× sales. Over the trailing twelve months it lost $93.28M on revenue of $20.80M and burned $73.05M of free cash flow. Revenue fell 76.6% year over year.
As of its latest reported balance sheet, it holds $191.48M in cash and securities against $22.93M of debt, a net cash position of $168.55M.
Arcturus Therapeutics Holdings does not currently pay a dividend.
The share price is down 10.6% over the past year. At $9.84 (the Oct 23, 2026 close) it sits within its 52-week range of $5.50 to $24.17, above its 200-day moving average of $8.84.
Based on 9 professional analyst ratings from the past 90 days, the consensus is Buy with an average price target of $21.29, 116.4% above the Oct 23, 2026 close.
Frequently Asked Questions About Arcturus Therapeutics Holdings
What is the current stock price for ARCT?
As of the Oct 23, 2026 close, ARCT stock trades at $9.84. The 52-week range is $5.50–$24.17, with a day range of $9.75–$10.69.
What is the P/E ratio for ARCT?
The P/E ratio (Price-to-Earnings) for ARCT is shown in the Key Statistics section. This valuation metric helps compare Arcturus Therapeutics Holdings Inc. to industry peers.
Does ARCT pay dividends?
Arcturus Therapeutics Holdings does not currently pay a regular dividend. It reported a net loss over the trailing twelve months, so it has no earnings to distribute. Check the Dividends tab for historical dividend information.
What do analysts recommend for ARCT?
Based on ratings from 9 professional analysts over the last 90 days, the consensus for ARCT is Buy. The average 12-month price target is $21.29, a 116.4% upside from the Oct 23, 2026 close of $9.84.
What is the market cap of ARCT?
As of the Oct 23, 2026 close, Arcturus Therapeutics Holdings's market capitalization is $279.7M, classifying it as a micro-cap company. Arcturus Therapeutics Holdings operates in the Healthcare sector within the Biotechnology industry.